Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

rento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the potential for approval and commercial success of Cynviloq; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento's proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento's filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Sorrento undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.  


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... June 30, 2015.  Revenue for the quarter was $453.1 ... ended June 30, 2014 (a 17 percent increase on ... consistent with the quarter ended June 30, 2014.  Diluted ... with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
(Date:8/2/2015)... ... ... Molecular biologists in New South Wales say a protein linked to cell ... an article on the new research. Click here to read it now. ... tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation with ...
(Date:8/1/2015)... ... 2015 , ... Western University of Health Sciences’ newest class ... growing percentage of U.S. physicians, and reflects the diversity of the communities where ... message delivered by John W. Becher, DO, president of the American Osteopathic Association, ...
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it is embarking ... The goal is to bring this Torah – dating from 1880 – back to ... religious services. , Scroll No. 515, from the town of Taus-Domazlice, is on ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has announced her ... to kick off the campaign for healing and Well-Being. , BeverlyD has helped women ... of raw, organic hair care products, as well as her book, Hair Now!— The ...
Breaking Medicine News(10 mins):Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2
... DEERFIELD, Ill., Oct. 15 Baxter International,(NYSE: BAX ... third,quarter 2007 financial results on Thursday, October 18, 2007, ... access the call, please dial,866-793-1307 (domestic) or 703-639-1309 (international). ... to the start of the call for the,operator to ...
... 20 Years of Public Company Experience, MOUNTAIN VIEW, Calif., ... the appointment of James B.,Hawkins, president and CEO of Natus ... "We are excited that Jim Hawkins has decided to ... chairman of the board at,IRIDEX. "Jim brings to our Board ...
... BOSTON, Oct. 15 It could be one of ... if they,re,turning away from their family in favor of their ... A study led by Simmons School of Social Work ... adolescents that they feel,valued by their family, and is an ...
... patient health, WASHINGTON, Oct. 15 The move ... patients to spend their own,money on medical care is ... their own lives. That is the conclusion of Kent ... to Spend Your Own,Money on Medical Care: A Common ...
... Transitioning to Independence, SAN FRANCISCO, Oct. ... relationship with national human resources,outsourcing company TriNet ... investment advisors and their employees. As part ... who custody,assets with Schwab will now be ...
... Cryo-Cell,International, Inc. (OTC Bulletin Board: CCEL) (the "Company"), ... cord blood banks, today,announced results for the third ... for the third quarter were approximately $4.6,million, remaining ... third quarter of 2006. The Company reported a ...
Cached Medicine News:Health News:James B. Hawkins Appointed to IRIDEX Board of Directors 2Health News:James B. Hawkins Appointed to IRIDEX Board of Directors 3Health News:A Best-Kept Secret of Your Teen: They Really Do Care What You Think, Simmons College Study Shows 2Health News:How to Beat the High Cost of Living 2Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 2Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 3Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 4Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 2Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 3Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 4Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 5
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: